Merck's Strategic Move: Advanced Talks to Acquire SpringWorks Therapeutics
Merck KGaA is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics. While a deal isn't finalized, SpringWorks' share value surged following the talks. This acquisition could bolster Merck's cancer treatment offerings amidst recent setbacks in drug trials and increased activity in the U.
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
We recently published an article titled Jim Cramer Discusses These 10 Stocks & An Outfit Better Than DeepSeek. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback